A COST-EFFECTIVENESS ANALYSIS OF ALOGLIPTIN IN COMPARISON TO SAXAGLIPTIN

被引：0
|
作者：
Wingate, L. T. [1 ]
Oishi, T. S. [1 ]
Ali, Shubar N. S. [1 ]
机构：
[1] Howard Univ, Washington, DC 20059 USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
10.1016/j.jval.2015.03.356
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB49
引用
收藏
页码：A61 / A61
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO SITAGLIPTIN AND SAXAGLIPTIN BASED ON CARDIOVASCULAR OUTCOME TRIALS
    Ramos, M.
    Foos, V
    Ustyugova, A., V
    Hau, N.
    Gandhi, P.
    Lamotte, M.
    VALUE IN HEALTH, 2018, 21 : S2 - S3
  • [2] Cost-effectiveness analysis of empagliflozin in comparison to standard of care, sitagliptin and saxagliptin based on cardiovascular outcomes trials
    Ramos, M.
    Foos, V.
    Ustyugova, A.
    Hau, N.
    Gandhi, P.
    Lamotte, M.
    DIABETOLOGIA, 2018, 61 : S425 - S425
  • [3] Cost-effectiveness analysis of alogliptin in type 2 diabetes mellitus: a payer perspective
    Patel, Dhruv
    Tai, Bik-Wai Bilvick
    Law, Anandi
    PHARMACOTHERAPY, 2013, 33 (10): : E268 - E268
  • [4] COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN RUSSIA
    Arinina, E. E.
    Rashyd, M.
    VALUE IN HEALTH, 2012, 15 (04) : A172 - A172
  • [5] SAXAGLIPTIN OR SULFONYLUREA AFTER METFORMIN SECONDARY FAILURE: A COST-EFFECTIVENESS ANALYSIS IN COLOMBIA
    Elgart, J. F.
    Gonzalez, L.
    Caporale, J. E.
    Aiello, E.
    Valencia, J. E.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2012, 15 (04) : A180 - A180
  • [6] COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF DIABETES MELLITUS TYPE 2 IN SPAIN
    Ramirez de Arellano, A.
    Brosa, M.
    Franch, J.
    Mauricio, D.
    Alvarez, C.
    Sanchez-Zamorano, M.
    De Rivas, B.
    VALUE IN HEALTH, 2010, 13 (07) : A292 - A292
  • [7] COST-EFFECTIVENESS OF SAXAGLIPTIN TREATMENT IN THREE LATIN AMERICAN COUNTRIES
    Elgart, J. F.
    Caporale, J. E.
    Aiello, E. C.
    Waschbusch, M.
    Jotimliansky, L.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2011, 14 (07) : A547 - A547
  • [8] US Cost-Effectiveness of Saxagliptin in Type 2 Diabetes Mellitus
    Bergenheim, Klas
    Williams, Setareh A.
    Bergeson, Joette Gdovin
    Stern, Lee
    Sriprasert, Michelle
    AMERICAN JOURNAL OF PHARMACY BENEFITS, 2012, 4 (01) : 20 - 28
  • [9] Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden
    Granstrom, Ola
    Bergenheim, Klas
    McEwan, Phil
    Sennfalt, Karin
    Henriksson, Martin
    PRIMARY CARE DIABETES, 2012, 6 (02) : 127 - 136
  • [10] Cost-Effectiveness of Saxagliptin in Type 2 Diabetes in the United States
    Bergenheim, Klas
    Williams, Setareh A.
    Bergeson, Joette G.
    Stern, Lee
    Sriprasert, Michelle
    DIABETES, 2011, 60 : A629 - A630
12345